Felicitex Therapeutics and Selvita Initiate Strategic Collaboration to Target Cancer Quiescence
Felicitex Therapeutics and Selvita announced that they have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors.
During the first phase of the collaboration the companies seek to discover and develop selective inhibitors of the cancer quiescence target kinase family, in order to generate multiple novel drug candidates against the quiescent cancer cells. The ultimate aim of the joint project is to deliver clinical candidates for unmet oncology indications. The companies plan joint projects on other targets related to cancer quiescence in the future.
It is currently well accepted in the scientific community that populations of malignant cells are highly heterogeneous and whereas some of the cancer cells divide rapidly, some of the cancer cells are quiescent. All currently available cancer chemotherapies target proliferating cancer cells. Quiescent cancer cells are invulnerable to these treatments because quiescent cells are not dividing. Moreover, when cancer cells are under stress, such as from chemotherapy, anti-angiogenesis therapy, or radiation, cancer cells often go to “sleep”, or use quiescent state as a niche to hide. After the completion of treatment, these cells begin growing again and cause cancer recurrence.
The alliance of Felicitex Therapeutics and Selvita allows to combine Felicitex’s experience in targeting cancer quiescence with Selvita’s significant know how on cancer quiescence target kinases, leading to a potentially breakthrough cooperation and delivery of much needed effective antineoplastic medicines.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Dr. Christie Hunter wins HUPO 2013 Science and Technology Award - AB SCIEX proteomics scientist is recognized for her role in advancing targeted proteomics
Probiodrug Further Expands Scientific Advisory Board by Appointing Prof Dr Dr hc Christian Haass
Anti-tumor protein isolated from ink of a sea slug destroys various kinds of cancers
List_of_papaya_diseases

New 'NanoZymes' use light to kill bacteria - Artificial enzymes could be used in hospitals and toilets
Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine for HPV-Induced Cervical Cancer

New Drug Candidates from Known Compounds - Big data platform for drug repurposing presented
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global Agreement
Gerhard Schratt, PhD and Professor Albert Sickmann receive the Analytica Research Prize
Elixir Pharmaceuticals and Siena Biotech S.p.A. enter Agreement to Evaluate SIRT1 Inhibitors in Huntington's Disease
GlaxoSmithKline and Genmab seek European Marketing Authorisation of Arzerra (Ofatumab) in Advanced Stage Blood Cancer
